Type I and type II Fc receptors regulate innate and adaptive immunity (original) (raw)

• Bournazos, S., Chow, S.K., Abboud, N., Casadevall, A. & Ravetch, J.V. Human IgG Fc domain engineering enhances antitoxin neutralizing antibody activity. J. Clin. Invest. 124, 725–729 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• DiLillo, D.J., Tan, G.S., Palese, P. & Ravetch, J.V. Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo . Nat. Med. 20, 143–151 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Nimmerjahn, F. & Ravetch, J.V. Fcγ receptors as regulators of immune responses. Nat. Rev. Immunol. 8, 34–47 (2008).
  Article CAS PubMed Google Scholar
• Nimmerjahn, F. & Ravetch, J.V. Antibody-mediated modulation of immune responses. Immunol. Rev. 236, 265–275 (2010).
  Article CAS PubMed Google Scholar
• Anthony, R.M. & Ravetch, J.V. A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs. J. Clin. Immunol. 30, S9–S14 (2010).
  Article CAS PubMed Google Scholar
• Bournazos, S., Woof, J.M., Hart, S.P. & Dransfield, I. Functional and clinical consequences of Fc receptor polymorphic and copy number variants. Clin. Exp. Immunol. 157, 244–254 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Sondermann, P., Pincetic, A., Maamary, J., Lammens, K. & Ravetch, J.V. General mechanism for modulating immunoglobulin effector function. Proc. Natl. Acad. Sci. USA 110, 9868–9872 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Nimmerjahn, F. & Ravetch, J.V. Fc-receptors as regulators of immunity. Adv. Immunol. 96, 179–204 (2007).
  Article CAS PubMed Google Scholar
• Nimmerjahn, F. & Ravetch, J.V. FcγRs in health and disease. Curr. Top. Microbiol. Immunol. 350, 105–125 (2011).
  CAS PubMed Google Scholar
• Ravetch, J.V. & Bolland, S. IgG Fc receptors. Annu. Rev. Immunol. 19, 275–290 (2001).
  Article CAS PubMed Google Scholar
• Smith, K.G. & Clatworthy, M.R. FcγRIIB in autoimmunity and infection: evolutionary and therapeutic implications. Nat. Rev. Immunol. 10, 328–343 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Kimberly, R.P. et al. Diversity and duplicity: human Fcγ receptors in host defense and autoimmunity. Immunol. Res. 26, 177–189 (2002).
  Article CAS PubMed Google Scholar
• Takai, T. Fc receptors and their role in immune regulation and autoimmunity. J. Clin. Immunol. 25, 1–18 (2005).
  Article CAS PubMed Google Scholar
• Jefferis, R. Isotype and glycoform selection for antibody therapeutics. Arch. Biochem. Biophys. 526, 159–166 (2012).
  Article CAS PubMed Google Scholar
• Narciso, J.E. et al. Analysis of the antibody structure based on high-resolution crystallographic studies. N. Biotechnol. 28, 435–447 (2011).
  Article CAS PubMed Google Scholar
• Nimmerjahn, F. & Ravetch, J.V. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 310, 1510–1512 (2005).
  Article CAS PubMed Google Scholar
• Krapp, S., Mimura, Y., Jefferis, R., Huber, R. & Sondermann, P. Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. J. Mol. Biol. 325, 979–989 (2003).
  Article CAS PubMed Google Scholar
• Teplyakov, A., Zhao, Y., Malia, T.J., Obmolova, G. & Gilliland, G.L. IgG2 Fc structure and the dynamic features of the IgG CH2–CH3 interface. Mol. Immunol. 56, 131–139 (2013).
  Article CAS PubMed Google Scholar
• Garman, S.C., Wurzburg, B.A., Tarchevskaya, S.S., Kinet, J.P. & Jardetzky, T.S. Structure of the Fc fragment of human IgE bound to its high-affinity receptor Fc epsilonRI alpha. Nature 406, 259–266 (2000).
  Article CAS PubMed Google Scholar
• Sondermann, P., Huber, R., Oosthuizen, V. & Jacob, U. The 3.2-A crystal structure of the human IgG1 Fc fragment-FcγRIII complex. Nature 406, 267–273 (2000).
  Article CAS PubMed Google Scholar
• Davies, A.M. et al. Structural determinants of unique properties of human IgG4-Fc. J. Mol. Biol. 426, 630–644 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Bruhns, P. et al. Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses. Blood 113, 3716–3725 (2009).
  Article CAS PubMed Google Scholar
• Kaneko, Y., Nimmerjahn, F. & Ravetch, J.V. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313, 670–673 (2006).
  Article CAS PubMed Google Scholar
• Lux, A. & Nimmerjahn, F. Impact of differential glycosylation on IgG activity. Adv. Exp. Med. Biol. 780, 113–124 (2011).
  Article CAS PubMed Google Scholar
• Shields, R.L. et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcγRIII and antibody-dependent cellular toxicity. J. Biol. Chem. 277, 26733–26740 (2002).
  Article CAS PubMed Google Scholar
• Scherer, H.U. et al. Glycan profiling of anti-citrullinated protein antibodies isolated from human serum and synovial fluid. Arthritis Rheum. 62, 1620–1629 (2010).
  Article CAS PubMed Google Scholar
• van de Geijn, F.E. et al. Immunoglobulin G galactosylation and sialylation are associated with pregnancy-induced improvement of rheumatoid arthritis and the postpartum flare: results from a large prospective cohort study. Arthritis Res. Ther. 11, R193 (2009).
  Article PubMed PubMed Central CAS Google Scholar
• Shinzaki, S. et al. IgG oligosaccharide alterations are a novel diagnostic marker for disease activity and the clinical course of inflammatory bowel disease. Am. J. Gastroenterol. 103, 1173–1181 (2008).
  Article PubMed Google Scholar
• Tomana, M., Schrohenloher, R.E., Koopman, W.J., Alarcon, G.S. & Paul, W.A. Abnormal glycosylation of serum IgG from patients with chronic inflammatory diseases. Arthritis Rheum. 31, 333–338 (1988).
  Article CAS PubMed Google Scholar
• Ferrara, C. et al. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcγRIII and antibodies lacking core fucose. Proc. Natl. Acad. Sci. USA 108, 12669–12674 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Borrok, M.J., Jung, S.T., Kang, T.H., Monzingo, A.F. & Georgiou, G. Revisiting the role of glycosylation in the structure of human IgG Fc. ACS Chem. Biol. 7, 1596–1602 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Albert, H., Collin, M., Dudziak, D., Ravetch, J.V. & Nimmerjahn, F. In vivo enzymatic modulation of IgG glycosylation inhibits autoimmune disease in an IgG subclass-dependent manner. Proc. Natl. Acad. Sci. USA 105, 15005–15009 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Barb, A.W. & Prestegard, J.H. NMR analysis demonstrates immunoglobulin G N-glycans are accessible and dynamic. Nat. Chem. Biol. 7, 147–153 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Wormald, M.R. et al. Variations in oligosaccharide-protein interactions in immunoglobulin G determine the site-specific glycosylation profiles and modulate the dynamic motion of the Fc oligosaccharides. Biochemistry 36, 1370–1380 (1997).
  Article CAS PubMed Google Scholar
• Anthony, R.M. et al. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 320, 373–376 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Anthony, R.M., Wermeling, F., Karlsson, M.C. & Ravetch, J.V. Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc. Natl. Acad. Sci. USA 105, 19571–19578 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Hess, C. et al. T cell-independent B cell activation induces immunosuppressive sialylated IgG antibodies. J. Clin. Invest. 123, 3788–3796 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Borthakur, S., Andrejeva, G. & McDonnell, J.M. Basis of the intrinsic flexibility of the Cɛ3 domain of IgE. Biochemistry 50, 4608–4614 (2011).
  Article CAS PubMed Google Scholar
• Dhaliwal, B. et al. Crystal structure of IgE bound to its B-cell receptor CD23 reveals a mechanism of reciprocal allosteric inhibition with high affinity receptor FcepsilonRI. Proc. Natl. Acad. Sci. USA 109, 12686–12691 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Selman, M.H. et al. Changes in antigen-specific IgG1 Fc N-glycosylation upon influenza and tetanus vaccination. Mol. Cell. Proteomics 11, M111.014563 (2012).
  Article PubMed CAS Google Scholar
• Espy, C. et al. Sialylation levels of anti-proteinase 3 antibodies are associated with the activity of granulomatosis with polyangiitis (Wegener's). Arthritis Rheum. 63, 2105–2115 (2011).
  Article CAS PubMed Google Scholar
• Oefner, C.M. et al. Tolerance induction with T cell-dependent protein antigens induces regulatory sialylated IgGs. J. Allergy Clin. Immunol. 129, 1647–1655 (2012).
  Article CAS PubMed Google Scholar
• Diaz de Ståhl, T. & Heyman, B. IgG2a-mediated enhancement of antibody responses is dependent on FcRγ+ bone marrow-derived cells. Scand. J. Immunol. 54, 495–500 (2001).
  Article PubMed Google Scholar
• Kalergis, A.M. & Ravetch, J.V. Inducing tumor immunity through the selective engagement of activating Fcγ receptors on dendritic cells. J. Exp. Med. 195, 1653–1659 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Sutterwala, F.S., Noel, G.J., Clynes, R. & Mosser, D.M. Selective suppression of interleukin-12 induction after macrophage receptor ligation. J. Exp. Med. 185, 1977–1985 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Boruchov, A.M. et al. Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. J. Clin. Invest. 115, 2914–2923 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Dhodapkar, K.M. et al. Selective blockade of inhibitory Fcγ receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells. Proc. Natl. Acad. Sci. USA 102, 2910–2915 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Blank, U., Launay, P., Benhamou, M. & Monteiro, R.C. Inhibitory ITAMs as novel regulators of immunity. Immunol. Rev. 232, 59–71 (2009).
  Article CAS PubMed Google Scholar
• Stuart, L.M. & Ezekowitz, R.A. Phagocytosis: elegant complexity. Immunity 22, 539–550 (2005).
  Article CAS PubMed Google Scholar
• Swanson, J.A. & Hoppe, A.D. The coordination of signaling during Fc receptor-mediated phagocytosis. J. Leukoc. Biol. 76, 1093–1103 (2004).
  Article CAS PubMed Google Scholar
• Regnault, A. et al. Fcγ receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J. Exp. Med. 189, 371–380 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Dhodapkar, K.M., Krasovsky, J., Williamson, B. & Dhodapkar, M.V. Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J. Exp. Med. 195, 125–133 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Schuurhuis, D.H. et al. Immune complex-loaded dendritic cells are superior to soluble immune complexes as antitumor vaccine. J. Immunol. 176, 4573–4580 (2006).
  Article CAS PubMed Google Scholar
• Desai, D.D. et al. Fcγ receptor IIB on dendritic cells enforces peripheral tolerance by inhibiting effector T cell responses. J. Immunol. 178, 6217–6226 (2007).
  Article CAS PubMed Google Scholar
• Mantovani, A. et al. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 25, 677–686 (2004).
  Article CAS PubMed Google Scholar
• Guilliams, M., Bruhns, P., Saeys, Y., Hammad, H. & Lambrecht, B.N. The function of Fcγ receptors in dendritic cells and macrophages. Nat. Rev. Immunol. 14, 94–108 (2014).
  Article CAS PubMed Google Scholar
• Jackson, S.M., Wilson, P.C., James, J.A. & Capra, J.D. Human B cell subsets. Adv. Immunol. 98, 151–224 (2008).
  Article CAS PubMed Google Scholar
• Fujiwara, H. et al. The absence of IgE antibody-mediated augmentation of immune responses in CD23-deficient mice. Proc. Natl. Acad. Sci. USA 91, 6835–6839 (1994).
  Article CAS PubMed PubMed Central Google Scholar
• Pearse, R.N. et al. SHIP recruitment attenuates FcγRIIB-induced B cell apoptosis. Immunity 10, 753–760 (1999).
  Article CAS PubMed Google Scholar
• Tew, J.G., Wu, J., Fakher, M., Szakal, A.K. & Qin, D. Follicular dendritic cells: beyond the necessity of T-cell help. Trends Immunol. 22, 361–367 (2001).
  Article CAS PubMed Google Scholar
• Barrington, R.A., Pozdnyakova, O., Zafari, M.R., Benjamin, C.D. & Carroll, M.C. B lymphocyte memory: role of stromal cell complement and FcγRIIB receptors. J. Exp. Med. 196, 1189–1199 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Ravetch, J.V. & Carroll, M.C. in Molecular Biology of B Cells (eds. Honjo, T., Alt, F.W. & Neuberger, M.S.) 275–287 (Elsevier, 2004).
• Ravetch, J.V. & Nussenzweig, M. Killing some to make way for others. Nat. Immunol. 8, 337–339 (2007).
  Article CAS PubMed Google Scholar
• Xiang, Z. et al. FcγRIIb controls bone marrow plasma cell persistence and apoptosis. Nat. Immunol. 8, 419–429 (2007).
  Article CAS PubMed Google Scholar
• González, D. et al. Classical dengue hemorrhagic fever resulting from two dengue infections spaced 20 years or more apart: Havana, Dengue 3 epidemic, 2001–2002. Int. J. Infect. Dis. 9, 280–285 (2005).
  Article PubMed Google Scholar
• Kliks, S.C., Nimmanitya, S., Nisalak, A. & Burke, D.S. Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am. J. Trop. Med. Hyg. 38, 411–419 (1988).
  Article CAS PubMed Google Scholar
• Kliks, S. Antibody-enhanced infection of monocytes as the pathogenetic mechanism for severe dengue illness. AIDS Res. Hum. Retroviruses 6, 993–998 (1990).
  Article CAS PubMed Google Scholar
• Duerr, A. et al. Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study). J. Infect. Dis. 206, 258–266 (2012).
  Article PubMed PubMed Central Google Scholar
• Monsalvo, A.C. et al. Severe pandemic 2009 H1N1 influenza disease due to pathogenic immune complexes. Nat. Med. 17, 195–199 (2011).
  Article CAS PubMed Google Scholar
• Guihot, A. et al. Low titers of serum antibodies inhibiting hemagglutination predict fatal fulminant influenza A(H1N1) 2009 infection. Am. J. Respir. Crit. Care Med. 189, 1240–1249 (2014).
  Article CAS PubMed Google Scholar
• Ubol, S. & Halstead, S.B. How innate immune mechanisms contribute to antibody-enhanced viral infections. Clin. Vaccine Immunol. 17, 1829–1835 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• El Bakkouri, K. et al. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J. Immunol. 186, 1022–1031 (2011).
  Article CAS PubMed Google Scholar
• Corti, D. et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333, 850–856 (2011).
  Article CAS PubMed Google Scholar
• Hessell, A.J. et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449, 101–104 (2007).
  Article CAS PubMed Google Scholar
• Abboud, N. et al. A requirement for FcγR in antibody-mediated bacterial toxin neutralization. J. Exp. Med. 207, 2395–2405 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Tedder, T.F., Baras, A. & Xiu, Y. Fcγ receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity. Springer Semin. Immunopathol. 28, 351–364 (2006).
  Article CAS PubMed Google Scholar
• Cartron, G. et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood 99, 754–758 (2002).
  Article CAS PubMed Google Scholar
• Weng, W.K. & Levy, R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol. 21, 3940–3947 (2003).
  Article CAS PubMed Google Scholar
• Clynes, R.A., Towers, T.L., Presta, L.G. & Ravetch, J.V. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med. 6, 443–446 (2000).
  Article CAS PubMed Google Scholar
• Uchida, J. et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J. Exp. Med. 199, 1659–1669 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Musolino, A. et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J. Clin. Oncol. 26, 1789–1796 (2008).
  Article CAS PubMed Google Scholar
• Varchetta, S. et al. Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2. Cancer Res. 67, 11991–11999 (2007).
  Article CAS PubMed Google Scholar
• Bibeau, F. et al. Impact of FcγRIIa-FcγRIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J. Clin. Oncol. 27, 1122–1129 (2009).
  Article CAS PubMed Google Scholar
• Smith, P., DiLillo, D.J., Bournazos, S., Li, F. & Ravetch, J.V. Mouse model recapitulating human Fcγ receptor structural and functional diversity. Proc. Natl. Acad. Sci. USA 109, 6181–6186 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Goede, V. et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N. Engl. J. Med. 370, 1101–1110 (2014).
  Article CAS PubMed Google Scholar
• Li, F. & Ravetch, J.V. Inhibitory Fcγ receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies. Science 333, 1030–1034 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• White, A.L. et al. Interaction with FcγRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody. J. Immunol. 187, 1754–1763 (2011).
  Article CAS PubMed Google Scholar
• Xu, Y. et al. FcγRs modulate cytotoxicity of anti-Fas antibodies: implications for agonistic antibody-based therapeutics. J. Immunol. 171, 562–568 (2003).
  Article CAS PubMed Google Scholar
• Wilson, N.S. et al. An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell 19, 101–113 (2011).
  Article CAS PubMed Google Scholar
• Li, F. & Ravetch, J.V. A general requirement for FcγRIIB co-engagement of agonistic anti-TNFR antibodies. Cell Cycle 11, 3343–3344 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Chuntharapai, A. et al. Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4. J. Immunol. 166, 4891–4898 (2001).
  CAS PubMed Google Scholar
• Li, F. & Ravetch, J.V. Antitumor activities of agonistic anti-TNFR antibodies require differential FcγRIIB coengagement in vivo . Proc. Natl. Acad. Sci. USA 110, 19501–19506 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Bulliard, Y. et al. Activating Fcγ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J. Exp. Med. 210, 1685–1693 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Simpson, T.R. et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J. Exp. Med. 210, 1695–1710 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Imbach, P. et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1, 1228–1231 (1981).
  Article CAS PubMed Google Scholar
• Anthony, R.M., Wermeling, F. & Ravetch, J.V. Novel roles for the IgG Fc glycan. Ann. NY Acad. Sci. 1253, 170–180 (2012).
  Article CAS PubMed Google Scholar
• Nimmerjahn, F. & Ravetch, J.V. Anti-inflammatory actions of intravenous immunoglobulin. Annu. Rev. Immunol. 26, 513–533 (2008).
  Article CAS PubMed Google Scholar
• Debré, M. et al. Infusion of Fcγ fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet 342, 945–949 (1993).
  Article PubMed Google Scholar
• Schwab, I. et al. Broad requirement for terminal sialic acid residues and FcγRIIB for the preventive and therapeutic activity of intravenous immunoglobulins in vivo . Eur. J. Immunol. 44, 1444–1453 (2014).
  Article CAS PubMed Google Scholar
• Crow, A.R. et al. IVIg-mediated amelioration of murine ITP via FcγRIIB is independent of SHIP1, SHP-1, and Btk activity. Blood 102, 558–560 (2003).
  Article CAS PubMed Google Scholar
• Crow, A.R., Song, S., Semple, J.W., Freedman, J. & Lazarus, A.H. IVIg inhibits reticuloendothelial system function and ameliorates murine passive-immune thrombocytopenia independent of anti-idiotype reactivity. Br. J. Haematol. 115, 679–686 (2001).
  Article CAS PubMed Google Scholar
• Tackenberg, B. et al. Impaired inhibitory Fcγ receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy. Proc. Natl. Acad. Sci. USA 106, 4788–4792 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Portman, M.A., Wiener, H.W., Silva, M., Shendre, A. & Shrestha, S. DC-SIGN gene promoter variants and IVIG treatment response in Kawasaki disease. Pediatr. Rheumatol. Online J. 11, 32 (2013).
  Article PubMed PubMed Central Google Scholar
• Crow, A.R., Song, S., Semple, J.W., Freedman, J. & Lazarus, A.H. A role for IL-1 receptor antagonist or other cytokines in the acute therapeutic effects of IVIg? Blood 109, 155–158 (2007).
  Article CAS PubMed Google Scholar
• Schwab, I., Biburger, M., Kronke, G., Schett, G. & Nimmerjahn, F. IVIg-mediated amelioration of ITP in mice is dependent on sialic acid and SIGNR1. Eur. J. Immunol. 42, 826–830 (2012).
  Article CAS PubMed Google Scholar